Nurix Therapeutics is a biotechnology company that is leading the field of protein modulation to develop innovative medicines for cancer and inflammatory diseases. The company leverages its proprietary DELigase platform to create small molecule drugs that harness the activity of E3 ligases, enzymes crucial for protein degradation within cells. Nurix's approach involves both targeted protein degradation, which eliminates specific disease-causing proteins, and targeted protein elevation, which prevents protein degradation to raise levels of beneficial proteins. Through its advanced pipeline, Nurix aims to meet the unmet medical needs of patients by empowering the body's natural ability to fight disease.
research β’ life sciences β’ biotechnology
201 - 500 employees
Founded 2015
𧬠Biotechnology
π Pharmaceuticals
π¬ Science
π° $40M Post-IPO Equity on 2022-07
February 20
Lead safety pharmacology and toxicology studies for drug development at Nurix Therapeutics.
πΊπΈ United States β Remote
π° $40M Post-IPO Equity on 2022-07
β° Full Time
π Senior
π Director
π¦ H1B Visa Sponsor
Remote Jobs at Nurix Therapeutics